<DOC>
	<DOCNO>NCT00666926</DOCNO>
	<brief_summary>Phase 1 safety , pharmacokinetics , pharmacodynamics trial focal adhesion kinase ( FAK ) inhibitor PF-00562271 patient positive Positron Emission Tomography [ PET ] scan due advance non-hematologic malignancy , include pancreatic , head neck , prostatic neoplasm , patient malignancy appropriate serial biopsy . Screening consists Fluorodeoxyglucose Positron Emission Tomography [ FDG-PET ] tumor imaging , medical history , physical examination , Eastern Cooperative Oncology Group [ ECOG ] performance status , blood draw , pregnancy test female patient childbearing potential . Treatment consist PF00562271 tablet continue progression disease , unacceptable toxicity , patient request . Evaluations bioactivity measure serial FDG-PET blood test biomarkers related FAK PYK2 kinase activity .</brief_summary>
	<brief_title>Study Of PF-00562271 , Including Patients With Pancreatic , Head And Neck , Prostatic Neoplasms</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<criteria>Pancreatic , head neck , prostatic neoplasm , patient nonhematologic malignancy tumor appropriate serial biopsy . Adequate organ function , include bilirubin le 1.5 x ULN , [ Eastern Cooperative Oncology Group ] ECOG performance status 02 . Clinically significant gastrointestinal abnormality , requirement systemic anticoagulant potent CYP 3A4 inhibitor , history clinically significant cardiac pulmonary disorder .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Pancreatic Neoplasm</keyword>
	<keyword>Head Neck neoplasm</keyword>
	<keyword>Prostatic neoplasm ; Focal Adhesion Kinase</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>FDG-PET</keyword>
</DOC>